Working… Menu
Trial record 53 of 131 for:    "Hepatitis" | "Lamivudine"

Safety and Antiviral Study of ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00040144
Recruitment Status : Terminated (Safety concerns)
First Posted : June 25, 2002
Last Update Posted : August 19, 2009
Information provided by:
Achillion Pharmaceuticals

Brief Summary:
The purpose of this study is to determine the safety and antiviral HBV activity of ACH126, 433 (b-L-Fd4C) in the treatment of adults with lamivudine-resistant chronic Hepatitis B.

Condition or disease Intervention/treatment Phase
Chronic Hepatitis B Drug: ACH126, 433 (b-L-Fd4C) Phase 2

Detailed Description:
Evaluation of safety and antiviral activity of 3 dose levels of ACH126, 443 over a twelve week treatment in the population described.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 85 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Safety and Efficacy of 12 Weeks Oral Treatment With ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B
Study Start Date : July 2002
Actual Study Completion Date : May 2003

Resource links provided by the National Library of Medicine

Drug Information available for: Lamivudine

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

  • Adults ≥ 18 years of age
  • Chronic HBV infection, known to be HbsAg positive ≥ 6 months
  • On lamivudine, either 100 or 150 mg daily for the treatment of chronic hepatitis B infection and
  • Exhibit a 2-3 log decrease in HBV DNA levels followed by a rebound of at least 1.5 log HBV DNA or

    • Achieved an HBV DNA level of <10,000 copies/mL HBV DNA on at least 2 occasions and have rebounded to > 100,000 copies/mL HBV DNA, or
    • Have a demonstrable 3TC resistant genotype regardless of treatment history.
  • HBeAG positive
  • HIV negative
  • Serum ALT ≥1.5 and ≤10x times upper limit of normal
  • HGB ≥10g/dl or HCT ≥30% (in the absence of blood transfusions or erythropoietin treatment in the preceding two weeks)
  • Platelet count >75,000/mm(^3), (in the absence of ongoing G-CSF therapy)
  • Serum creatinine <1.1 times upper limit of normal (ULN)
  • Negative radiologic screening test (ultrasound, CT scan or MRI) for hepatocellular carcinoma (HCC) within 6 months prior to entry
  • PT/INR<2
  • Subjects of reproductive capability must utilize an approved forms of birth control
  • All women of child-bearing capability must have a negative serum or urine pregnancy test (minimum sensitivity of 24 IU/L of b-HCG) within 72 hours prior to the start of study medication
  • Subjects must be able to provide written informed consent
  • Subject must be available for follow-up for a period of 20 weeks

Exclusion Criteria

  • HIV infection
  • Hepatitis C co-infection
  • Alcohol abuse
  • Pregnancy or breast-feeding
  • Inability to tolerate oral medication
  • Any clinical condition or prior therapy that, in the Investigator's opinion, would make the subject unsuitable for the study or unable to comply with the dosing requirements
  • Use of any investigational drug
  • Patients with decompensated liver disease
  • Use of any concomitant herbal treatments

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00040144

Layout table for location information
United States, California
Cedars Sinai Medical Center
Los Angeles, California, United States, 90048
University of California-Irvine
Orange, California, United States, 92868
Huntington Memorial Hospital
Pasadena, California, United States, 91105
University of California-San Francisco
San Francisco, California, United States, 94143-0538
United States, Florida
University of Miami
Miami, Florida, United States, 33136
United States, Illinois
University of Illinois at Chicago
Chicago, Illinois, United States, 60612-7323
University of Chicago
Chicago, Illinois, United States, 60637
United States, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215
United States, New York
Cornell Weill Medical College
New York, New York, United States, 10021
United States, Texas
Baylor Universtiy Medical Center
Dallas, Texas, United States, 75246
Southwest Infectious Disease Associates, P.A.
Dallas, Texas, United States, 75246
The University of Texas
Dallas, Texas, United States, 75390
United States, Virginia
Metropolitan Research
Fairfax, Virginia, United States, 22031
United States, Washington
Unviversity of Washington
Seattle, Washington, United States, 98195
Canada, British Columbia
Vancouver General Hospital
Vancouver, British Columbia, Canada, V5Z 1L5
Canada, Ontario
Toronto General Hospital
Toronto, Ontario, Canada, M5G 2C4
Toronto Western Hospital
Toronto, Ontario, Canada, M5T 2S8
Canada, Quebec
University of Montreal
Montreal, Quebec, Canada, H2X 3J4
The University of Hong Kong
Hong Kong SAR, China
Sponsors and Collaborators
Achillion Pharmaceuticals

Additional Information:
Layout table for additonal information Identifier: NCT00040144     History of Changes
Other Study ID Numbers: ACH443-005
First Posted: June 25, 2002    Key Record Dates
Last Update Posted: August 19, 2009
Last Verified: August 2009
Keywords provided by Achillion Pharmaceuticals:
E-Antigen positive,
Lamivudine-Resistant Chronic Hepatitis B,
Additional relevant MeSH terms:
Layout table for MeSH terms
Hepatitis A
Hepatitis B
Hepatitis B, Chronic
Hepatitis, Chronic
Hepatitis, Viral, Human
Liver Diseases
Digestive System Diseases
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Hepadnaviridae Infections
DNA Virus Infections
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Anti-HIV Agents